Takeda Pharmaceutical (TAK) Total Liabilities (2017 - 2026)

Takeda Pharmaceutical has reported Total Liabilities for 10 years, with the latest figure at $50.8 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 3.07% year-over-year to $50.8 billion in Q2 2026; TTM through Jun 2026 was $50.8 billion, a 3.07% increase from a year earlier, with the FY2026 full-year figure at $51.5 billion, up 7.34% from the prior year.
• Total Liabilities was $50.8 billion for Q2 2026 at Takeda Pharmaceutical, down from $51.5 billion in the prior quarter.
• The five-year high for Total Liabilities was $64.5 billion in Q1 2022, with the low at $47.9 billion in Q1 2025.
• Average Total Liabilities over 5 years is $53.4 billion, with a median of $51.7 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities retreated 19.96% in 2022, then grew 7.51% in 2026.
• Over 5 years, Total Liabilities stood at $51.9 billion in 2022, then retreated by 2.44% to $50.6 billion in 2023, then fell by 0.08% to $50.6 billion in 2024, then declined by 0.22% to $50.5 billion in 2025, then increased by 0.78% to $50.8 billion in 2026.
• The last three Total Liabilities figures came in at $50.8 billion (Q2 2026), $51.5 billion (Q1 2026), and $50.5 billion (Q4 2025), per Business Quant data.